Home » Stocks » FIXX

Homology Medicines, Inc. (FIXX)

Stock Price: $6.81 USD -0.22 (-3.13%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $6.80 -0.01 (-0.15%) Apr 16, 6:50 PM
Market Cap 388.74M
Revenue (ttm) 2.70M
Net Income (ttm) -128.69M
Shares Out 45.91M
EPS (ttm) -2.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $6.81
Previous Close $7.03
Change ($) -0.22
Change (%) -3.13%
Day's Open 7.02
Day's Range 6.56 - 7.11
Day's Volume 910,043
52-Week Range 6.56 - 17.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership -

6 days ago - GlobeNewsWire

Dilution is on the way thanks to the company's latest stock offering.

1 week ago - The Motley Fool

BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for...

1 week ago - GlobeNewsWire

BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subjec...

1 week ago - GlobeNewsWire

Homology Medicines (FIXX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...

3 weeks ago - Zacks Investment Research

Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End -

1 month ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing...

Other stocks mentioned: NVS
1 month ago - Benzinga

- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication -

1 month ago - GlobeNewsWire

- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease -

2 months ago - GlobeNewsWire

Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102...

3 months ago - Seeking Alpha

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -

5 months ago - GlobeNewsWire

Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors to Know Ab...

5 months ago - InvestorPlace

Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET

5 months ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

San Francisco, California--(Newsfile Corp. - October 29, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...

5 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - October 27, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...

5 months ago - Newsfile Corp

HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers

5 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hom...

5 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - October 20, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...

5 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - October 16, 2020) -  Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inv...

6 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz continues its investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of in...

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homolo...

6 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

6 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTIONS--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

6 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of inv...

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

6 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIX...

6 months ago - Business Wire

BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual confer...

7 months ago - GlobeNewsWire

Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU

8 months ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

- Executive with Extensive Rare Disease Expertise in Global Finance and  Commercial Operations -

8 months ago - GlobeNewsWire

Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

 -  Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications -

10 months ago - GlobeNewsWire

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, GTHX, IMGN, KDMN, VKTX
10 months ago - Kiplinger

- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing  for PKU -

11 months ago - GlobeNewsWire

Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for  Adults with PKU -

1 year ago - GlobeNewsWire

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of genetic therapy company Homology Medicines Inc (NASDAQ: FIXX) were moving to the downside Wednesday.

1 year ago - Benzinga

- Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial -

1 year ago - GlobeNewsWire

- Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology’s Senior Management - 

1 year ago - GlobeNewsWire

BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary adeno-...

1 year ago - GlobeNewsWire

About FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the live... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Arthur Tzianabos
Employees
205
Stock Exchange
NASDAQ
Ticker Symbol
FIXX
Full Company Profile

Financial Performance

In 2020, FIXX's revenue was $2.70 million, an increase of 62.18% compared to the previous year's $1.67 million. Losses were -$128.69 million, 23.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 27.00, which is an increase of 296.48% from the latest price.

Price Target
$27.00
(296.48% upside)
Analyst Consensus: Strong Buy